AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Notch mutations in subjects with recurrent or metastatic adenoid cystic carcinoma treated with rivoceranib from study RM-202 (AACR 2025) - "Previously unreported pathogenic NOTCH1-4 mutations were identified in ACC tumor samples from the RM-202 phase II trial. High rates of NOTCH4 L16 mutations suggest a novel mechanism of Notch pathway activation in ACC and represents a potential therapeutic target in this rare disease."

Clinical • Metastases • Adenoid Cystic Carcinoma • Oncology • NOTCH1 • NOTCH4

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC (clinicaltrials.gov) - P=N/A | N=97 | Active, not recruiting | Sponsor: First Hospital of China Medical University

Checkpoint inhibition • Combination therapy • Metastases • New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Tyrosine kinase inhibitors in Ewing's sarcoma: a systematic review. (PubMed, BMC Cancer) - "Various tyrosine kinase inhibitors (TKIs), including apatinib, anlotinib, and cabozantinib have shown clinical promise in patients with recurrent ES who have progressed on previous lines of therapy...Furthermore, biomarkers predictive of response are necessary to improve patient outcomes. In order to optimize ES care, considerations for patient eligibility on the basis of positivity for biomarkers predictive of response, and the inclusion of quality-of-life evaluations in studies must be addressed."

Journal • Review • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • HGF • IGF1 • KIT

CCGLC-001: Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Ze-yang Ding, MD | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): a multi-center, single-arm, phase 2 clinical trial (ELCC 2025) - P=N/A, P2 | "The phase III ETER701 clinical trial demonstrated the survival benefits of adding anlotinib to benmelstobart and chemotherapy, but the risks of hemoptysis and occult blood test positive cannot be ignored. The primary endpoint is progression-free survival (PFS). The secondary endpoints include objective response rate, disease control rate, PFS2, duration of response, overall survival, and safety."

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Updated network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: consistent role of TACE (EASL 2025) - " Transarterial chemoembolization (TACE) combined with lenvatinib provided the greatest improvement in OS compared to sorafenib, with a hazard ratio of 0.41 (95% confidence interval, 0.30–0.58), followed by sintilimab+IBI305 (0.57; 0.43–0.75), camrelizumab+rivoceranib (0.62; 0.48–0.80), atezolizumab+bevacizumab (0.66; 0.51– 0.85), lenvatinib+pembrolizumab (0.77; 0.62–0.97), and tremelimumab+durvalumab (0.78; 0.64–0.95). Our first-line analysis consistently scored TACE+lenvatinib best for survival outcomes, followed by various immunotherapy-based combinations in advanced HCC. This hierarchy was sustained in aggressive tumors or hepatitis B carriers."

Metastases • Retrospective data • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis (EASL 2025) - " Ten studies, enrolling 7,268 patients treated with Sorafenib, Lenvatinib, Nivolumab, Tislelizumab, Durvalumab, Atezolizumab+Bevacizumab, Sintilimab+IBI305, Durvalumab+Tremelimumab, Nivolumab+Ipilimumab, Atezolizumab+Cabozantinib, Lenvatinib+Pembrolizumab, Camrelizumab+Apatinib were included... Atezolizumab plus Bevacizumab was associated with the highest magnitude in reducing the risk of deterioration of most HR-QoL domains compared to other systemic therapies. Integrated assessment of OS with HR-QoL assessed by MDC suggests atezolizumab plus bevacizumab to provide the best balance between QoL preservation and OS benefit compared to other systemic therapy options in unresectable/advanced HCC."

HEOR • Metastases • Retrospective data • Fatigue • Hepatocellular Cancer • Hepatology • Oncology • Pain • Solid Tumor

Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05156970 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT 03612219 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P2 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

STAR-01: A randomized phase III clinical trial comparing PD-1 combined with apatinib and SOX,PD-1 combined with SOX, versus SOX alone in patients with advanced gastric adenocarcinoma. (ASCO 2025) - P4 | "Clinical Trial Registration Number: ChiCTR2000028845 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P3 data • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • PD-1

Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT05613478 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Checkpoint inhibition • Combination therapy • Retrospective data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial. (ASCO 2025) - "Clinical Trial Registration Number: NCT06670107 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT04724226 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Updated results of camrelizumab (Cam) plus low dose apatinib combined with gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract cancer (BTC): A single center, phase Ib/II trial. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT05742750 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P1/2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05451290 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology

Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026). (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05447702 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05512481 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Melanoma • Oncology • Solid Tumor

Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2200057726 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P2 data • Gastric Cancer • Hepatology • Oncology • Solid Tumor • HER-2

Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2100042938 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P2 data • Chordoma

Systemic Therapy for Advanced HCC (APASL 2025) - "Recently, four immunotherapy-based combination, namely the atezolizumab-bevacizumab, tremelimumab-durvalumab, camrelizumab-rivoceranib and ipilimumab-nivolumab have shown to improve overall survival of patients as compared to monotherapy TKI. The lecture will review the results of key clinical trials and discuss the future development."

Metastases • Hepatocellular Cancer • Hepatology

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P3 | N=682 | Recruiting | Sponsor: Zuoyi Jiao | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • PD-L1

The study of "Double Ai" combination combined with chemotherapy as the first-line treatment for alpha-fetoprotein-producing gastric cancer was published in the Nature sub-journal STTT [Google translation] (Jiangsu Hengrui Press Release) - P2 | N=64 | NCT04609176 | "36 patients received treatment and underwent tumor evaluation, 2 patients achieved complete remission (CR), 22 achieved partial remission (PR), and the confirmed ORR was 66.7% (95% CI: 49.0-81.4). The DCR was 88.9% (95% CI: 73.9-96.9). The mDoR was 8.4 months, and the time to remission (TTR) was 1.4 months. As of the data cutoff date, the median follow-up time was 11.7 months (range: 3.2-37.9). A total of 23 PFS events and 17 OS events occurred. The median PFS was 7.8 months (95% CI: 4.9-12.3). The 9-month and 12-month PFS rates were 39.2% and 35.3%, respectively. The median OS was 18.0 months (95% CI: 10.5-NR). The 9-month and 12-month OS rates were 76.7% and 67.0%, respectively."

P2 data • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma

Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report. (PubMed, Case Rep Oncol) - "Limited treatment options are available for residual locally advanced cervical cancer after concurrent radio-chemotherapy. Camrelizumab is affordable, at just 10% of the price of pembrolizumab, although it is similarly not covered by medical insurance for cervical cancer in China. The PTEN, PIK3CA, MTOR, and ARID1A gene mutations hold the potential to serve as predictive biomarkers for cervical cancer patients treated by PD-1 inhibitors."

IO biomarker • Journal • Cervical Cancer • Gastroenterology • Hematological Disorders • Hepatitis C • Liver Failure • Neutropenia • Oncology • Solid Tumor • ARID1A • PD-L1 • PIK3CA • PTEN

Targeting TIME in Advanced Hepatocellular Carcinoma: Mechanisms of Drug Resistance and Treatment Strategies. (PubMed, Crit Rev Oncol Hematol) - "Current systemic treatments for advanced HCC include VEGF-targeted tyrosine kinase inhibitors (Sorafenib, Lenvatinib), and the combination therapy of anti PD-1/PD-L1 and anti VEGF (Atezolizumab plus Bevacizumab, Camrelizumab plus Rivoceranib). This article reviews the mechanism of TIME promoting drug resistance, discusses the influence of current systemic HCC treatment drugs on TIME, and evaluates how these TIME changes affect the efficacy of treatment. A deeper understanding of the interaction between TIME and systemic treatment drugs may be beneficial to enhance the treatment effect, mitigate drug resistance of advanced HCC, and ultimately improve the prognosis of patients."

Journal • Review • Hepatocellular Cancer • Hepatology • Immune Modulation • Immunology • Liver Cancer • Oncology • Solid Tumor